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ABSTRACT 
 
Background:  The number of mobile phone users has grown explosively, which has 
generated mounting public concern regarding possible health hazards. This study aims 
to assess pituitary tumor risk as it has rarely been investigated. 
Materials and Methods: A case-control study was conducted with eligible cases 
identified from all five university hospitals in Finland and frequency-matched controls 
from national population register. Controls were matched to cases by age, sex, region of 
residence and date of interview. A detailed history of mobile phone use was obtained by 
a structured interview. Several indicators of mobile phone use were assessed using 
conditional logistic regression. 
Results: A reduced odd ratio was seen among regular mobile phone users (OR 0.39, 
95% confidence interval, CI: 0.21, 0.72) relative to never/non-regular users, possibly 
reflecting methodological limitations. Pituitary tumor risk was not increased after 10 or 
more years since first use (OR 0.69, 95% confidence interval, CI: 0.25, 1.89).The risk 
was not increased in relation to duration or, cumulative hours of use or cumulative 
number of calls. The results were similar for analogue and digital phones. 
 Conclusions: No excess risk was found to be associated with self-reported short- or 
medium-term use of mobile phone. This is consistent with most of the published 
studies. However, uncertainties remained for longer duration of use, as very small 
proportion of study participants reported use beyond 10 years. 
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1. INTRODUCTION 
 
Over the past few decades, wireless technology including mobile phone use has rapidly 
increased, which has drawn attention about possible health risks-predominantly an 
increased risk of brain tumors because of the proximity of exposure. The International 
Telecommunication has estimated that the number of mobile phone subscriptions will 
reach 7 billion in the year 2014, which is equivalent to 95.5 percent of the world 
population
 
[1]. Therefore, there is much interest in understanding the relationship 
between mobile phone use and brain tumors because even a small increase in risk might 
result large number of affected people. Mobile phone emits radiofrequency energy, a 
form of electromagnetic radiation which can be absorbed by the tissues closest to the 
phone and in May 2011, the International Agency for Research on Cancer (IARC) 
classified radiofrequency electromagnetic fields (RF-EMF) as ‘possibly carcinogenic to 
humans’ (Group 2B) based on limited evidence from epidemiological studies [2]. The 
American Cancer Society responded to IARC classification of cell phones as possible 
carcinogenic, stating that there could be some risk but the evidence is uncertain and 
needs to be investigated further and limiting cell phone use seems reasonable in the 
light of this uncertainty [3]. 
 
The mobile phones emit radiofrequency radiation which does not have sufficient energy 
to damage DNA directly [4]. It is generally agreed that radiofrequency radiation emitted 
by mobile phone can result in a small rise in tissue temperature of the brain and adjacent 
organs, but studies have shown weak evidence for related mechanisms of carcinogenesis 
[5]. To date, several epidemiological studies have been published reporting the effect of 
mobile phone use on tumor risk but most studies focused on glioma, meningioma and 
acoustic neuroma [6-13], with few studies focusing on salivary gland tumors, leukemia 
or lymphoma [14-17]. Most studies are based on case-control approach depending on 
participants’ self-reported exposure and only few are cohort studies. Only a limited 
number of studies have shown some evidence of association of cell phone use and the 
development of brain tumors among long-term users, analogue phones and ipsilateral 
use [18,19], but it is uncertain whether it is a true association or due to recall bias and 
other methodological limitations. However, most of the studies found no evidence of 
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increased risk [6, 8, 9, 10]. So far, pituitary tumor risk in relation to mobile phone use 
has been investigated in only three studies [20, 21, 22]. A similar conclusion was drawn 
from the two studies that there is no association between mobile phone use and the risk 
of pituitary tumors [20,21], in contrast another study found a raised relative risk in 
short-term mobile phone users with duration less than 5 years, but no evidence of trend 
with increasing duration of use [22]. 
 
In the late 1990s, several expert groups recommended research on the possible health 
effects of mobile phone use. As a result, the International Agency for Research on 
Cancer (IARC) coordinated a feasibility study in 1998 and 1999 and found that an 
international study to investigate the effect of mobile phone use and tumor risk would 
be feasible. A collaborative case-control study, the INTERPHONE study on brain 
tumors and mobile phone use was initiated in 2000 to increase the knowledge on 
possible health effects of mobile phone use in 13 countries (Australia, Canada, 
Denmark, Finland, France, Germany, Israel, Italy, Japan, New Zealand, Norway, 
Sweden and the UK) around the world coordinated by the IARC [23].
 
Interphone study 
is the largest case-control study of mobile phone use and brain tumors so far and 
includes the largest number of users with at least 10 years of exposure.  
 
This population based case-control study with 80 pituitary tumor cases and 240 controls 
was conducted as part of the Interphone study. The aim of this study was to evaluate the 
risk of pituitary tumor in relation to mobile phone use and specifically to assess 
pituitary tumor risk in relation to several indicators of mobile phone use such as years 
since first use, total duration of use, cumulative number of calls and cumulative hours of 
use. For comparison, we also evaluated the risk associated with analog and digital 
phone. 
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2. LITERATURE REVIEW 
 
In this chapter, author has reviewed a collection of research publications that are 
relevant and important in this thesis. The aim of this literature was to find whether there 
are similar researches related to the mobile phone use and brain tumors. Also, other 
related concepts that could be useful in this thesis are presented. 
 
2.1 Mobile phone 
 
2.1.1 History of mobile phone 
 
The development of the wireless communication system began with the use of ‘Walkie-
talkies’ during the Second World war in the 1930s to enable contact between foot 
soldiers and headquarters [24]. In 1946, AT-&-T and Southwestern Bell introduced the 
first American commercial radiotelephone service meant to connect mobile users in cars 
and the public fixed network [25]. Ericsson, a Swedish multinational provider of 
communications technology and services, introduced the world’s first fully automatic 
mobile telephone system in 1956 which was commercially released in Sweden, which 
opened the way for today’s mobile broadband networks [26].  The Improved Mobile 
Telephone Service (IMTS) launched by the Bell System in the 1960s offered direct dial 
rather than connecting through an operator and the first analog cellular systems were 
based on IMTS [27]. These systems were not cellular and were very expensive. One of 
the first and successful public commercial mobile phone networks was Finland’s ARP 
network (Auto-radio puhelin in Finnish or car radio phone in English) launched in 1971. 
ARP is also considered as a zero-generation cellular network being slightly above 
limited coverage networks [28]. The first hand-held mobile phone was introduced by 
John F. Mitchell [29] and Dr. Martin Cooper of Motorola in 1973 using around 2 kg 
handsets [30]. Prior to 1973, cellular mobile phone technology was only limited to 
phones installed in car and other vehicles.  
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Wireless communication systems have been classified into several generations: First 
Generation (1G), Second Generation (2G), Third Generation (3G) and Fourth 
Generation (4G). 
First Generation (1G): First generation of wireless telephone technology is analog 
telecommunications. In 1979, the world’s first mobile phone network was launched into 
commercial production in Tokyo, Japan by Nippon Telegraph and Telephone 
Corporation, commonly known as NTT. This was followed by Nordic Mobile 
Telephone (NMT) in the Nordic countries in 1981. This was the first mobile phone 
technology allowing international use of the mobile phone or ‘roaming’. The analog 
first generation mobile telephone was able to carry voice only and was replaced by 2G 
digital telecommunications [31]. 
 
Second Generation (2G): In addition to the voice service of analog phone, the second 
generation introduced short message service (SMS), i.e. text messages. It also 
introduced features to download ringtones and games. The second generation mobile 
telephony were commercially projected on Global System for Mobile Communications 
(GSM) standards and the world’s first commercial GSM network was launched in 
Finland in 1991 [32].  
 
Third Generation (3G): The third generation (3G) pre-commercial Wideband Code 
Division Multiple Access (WCDMA) trail network was launched by NTT DoCoMo in 
Japan, Tokyo in 2001 and then spread to Europe and USA in 2002 [33]. The technology 
is founded on International Telecommunication Union (ITU) which belongs to the IMT-
2000. The 3G technologies are widely used due to enhanced security and encryption 
features. It has improvements in screen displays and the ability to handle multimedia 
data, such as graphics and video streaming. 
 
Fourth Generation (4G): After the success of ITU defined IMT 2000 (3G) systems, 
ITU-R launched the IMT advanced (4G) initiatives [34]. 4G is better described as 
MAGIC (mobile multimedia, any-time anywhere, global mobility support, integrated 
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wireless solution, and customized personal service). 4G is intended to deliver extremely 
high quality video, show live image (stream video) and allow faster data transfer [35]. 
 
 
2.1.2 Expansion of mobile phone use 
 
Mobile phones have become ubiquitous in our society. The number of mobile phone 
users has risen sharply since the early 1990’s when the first digital mobile phones were 
introduced [36]. According to the estimation of International Telecommunication, the 
global penetration of mobile phone subscriptions will reach 7 billion in the year 2014 
[1].  
 
For a long time, Finland remained as one of the most advanced markets for mobile 
services. The number of telecommunication subscriptions in Finland quadrupled in 20 
years. In 1988, total telephone subscriptions in Finland were about 2.6 million including 
140,000 mobile phone subscriptions. At the end of 2008, there were over 10 million 
telecommunication subscriptions, fixed telephone network subscriptions numbered 
approximately 1.7 million, broadband subscriptions nearly 2.1 million and mobile 
phone subscription taking the highest position i.e. 6.9 million which is equal to 130 
subscriptions per 100 populations. [37]. By the end of 2012, the number of mobile 
network subscriptions was 9.3 million [38]. Apart from mobile telephones and their 
base stations, the demand for other wireless services (radio, microwave ovens, 
broadcasting radio and television signals, radar and other wireless networks) has been 
growing rapidly among general public. Among all, mobile phones are of greater concern 
in terms of their safety and potential health hazards specifically due to short-term or 
long-term exposure to radiofrequency (RF) radiation as mobile phones are used very 
close to the head and neck.  
 
Mobile phone use has been increasing dramatically as new technologies and 
applications are continually evolving such as text messaging, internet access, cameras, 
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calendars, music, email combined with standard telephone functions. It has become a 
social and cultural phenomenon [39] to send or receive text messages, send or receive 
email, download applications, get directions or location based information, listen to 
music, participate in video call or video chat [40]. Moreover, mobile phones have 
important contributions to narrow the gap in telephone usage between highly developed 
and less developed countries [41]. Interestingly, several studies have indicated that text 
messaging can help college students to quit smoking successfully [42]. In addition, cell 
phone facilitates communication with health care professionals where face to face 
communication is impossible [43]. 
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2.2 Brain tumors 
 
2.2.1 Definition and histological distribution of brain tumors 
 
Tumors are defined according to their histology and location. In this thesis, the term 
‘brain tumor’ is used to cover tumors occurring in the central nervous system (CNS), 
such as gliomas, meningiomas, acoustic neuromas and pituitary tumors even though the 
tumors are not always histologically originated from brain cells such as meningiomas 
originating from the meninges. 
 
The most common primary brain tumors are gliomas and meningiomas each accounting 
for one third of all primary CNS tumors. Nerve sheath tumors account for 9% of all 
tumors (acoustic neuromas account for 63% of all nerve sheath tumors). Other primary 
CNS tumors include pituitary tumors (13%), lymphomas less than 3% and 
craniopharyngiomas less than 1%. [44] 
 
 
2.2.2 Incidence of brain tumors 
 
The burden of cancer varies across countries according to differences in risk factors, 
detection practices, and availability of treatment, age structure and completeness of 
reporting [45]. A large number of reports have indicated an increasing incidence of 
brain tumor from the late 1970s to early 1990s in the elderly [46, 47, 48,49,50] and in 
children [51, 52,53]. The exact reason and mechanism for this increasing trend is still 
unclear but concurring with the introduction and widespread use of improved 
diagnostics. Computerized tomography (CT) scanner was used for the first time in 
University hospital in Tokyo in 1975 and became widely available in the following two 
decades [54].  
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A study, summarizing the results from the U.S National Council on Radiation 
Protection and Measurements (NCRP) and United Nations Scientific Committee on 
Effects of Atomic Radiations (UNSCEAR) found that in United States, the frequency of 
diagnostic radiological examination increased by 10 fold during 1950-2006. Worldwide, 
the frequency of CT scanning increased from one to three procedures per 1000 
population during 1977-1980 to about 35 procedures per 1000 population during 1997-
2007 [55]. Among elderly North Americans, two fold increases in brain cancer 
incidence was observed within 2 decades and they identified CT scan and MRI as a key 
factor responsible for that observed trends [56].  
 
For recent trends, epidemiological studies have mixed findings, some studies report 
increasing trend [57, 58,59] where as other report decreasing [60,61]. 
 
There is geographical variation in the incidence rates of brain tumors. The incidence 
rate for malignant brain tumors in Japan is less than half of that in Northern Europe 
[62]. The worldwide incidence rate of primary malignant brain and CNS tumors in 2012 
was 3.4 per 100,000. The incidence rates tend to be higher in more developed countries 
(5.1 per 100,000) than in less developed countries (3.0 per 100,000) [63]. This may also 
be caused by difference in both diagnosing and registering cases as well as in access to 
health care. 
 
Malignant gliomas are 40% more common among men than among women [64]. One of 
the studies has reported an increasing trend of gliomas in Nordic countries, however; 
the increase in the incidence was less than 1% (0.6% for men and 0.9% for women) for 
the years 1969-1998 [65]. Another similar study from 1974-2003, found even less pro-
nounced increase for gliomas (0.5% for men and 0.2% for women) [66]. 
 
Unlike gliomas, meningiomas are more common among women than among men 
[67,68]. In the analysis of 134,509 primary CNS tumors across the whole of England 
from 1979 through 2003, a statistically non-significant annual increase of approximately 
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1% was reported for young people (0-24 years) in meningioma incidence. In contrast, a 
significant increase of 3% was found for the elderly (over 65 years). [69] 
 
Brain tumours were the 11
th
 most common cancer types among males and 8
th
 among 
female in Finland in 2012. According to Finnish cancer registry, age-adjusted incidence 
rates of cancer per 100,000 person-years in 2012 for male was 11.0 and for female 13.2 
[70]. 
 
 
2.2.3 Classification and incidence of pituitary tumors 
 
Pituitary tumors are classified as either micro-adenomas (less than 10mm in diameter) 
or macro-adenomas (equal or greater than 10mm) [71]. Furthermore, they are classified 
as functional (prolactin producing, Adrenocorticotrophic (ACTH) producing, Growth 
hormone (GH) producing, Thyroid Stimulating Hormone (TSH) producing, 
glycoprotein producing) or non-functional depending on their hormonal activity [72]. 
About 30% of pituitary adenomas are prolactinomas, 15% are GH producing, 10% are 
ACTH producing, 10% are glycoprotein producing, and less than 1% secrete TSH. 
About 25% of pituitary tumors are non-secretory adenomas [73].  
 
Most of the epidemiological studies have focused on glioma, meningioma, acoustic 
neuroma through case-control studies, cross-sectional studies, cohort studies and meta-
analysis but pituitary tumors have rarely been investigated [21]. Due to the benign 
nature of pituitary tumors, most cancer registration systems do not record it, therefore 
data on the incidence, prevalence and trend of pituitary tumor is very limited [72].  
 
Although classically considered to be rare, pituitary tumors account for approximately 
13% of all primary brain tumors, being the third most common primary brain tumor in 
adults after meningiomas and gliomas [74]. The peak incidence of pituitary tumors 
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occur at age 30-60 years, earlier in women (20-45 years) than in men (35-60 years), as 
women are more sensitive to hyper-prolactinemic effect such as amenorrhea [75,76]. 
Some studies have reported higher incidence of pituitary tumors among American 
blacks compared with whites [75,77], however some disclose no racial difference in 
incidence rates [78]. 
 
In a descriptive study of primary brain tumors and central nervous system tumors, 
Central Brain Tumor Registry of the United States (CBTRUS) with 5 years of incidence 
data from (1990-1994) found that pituitary tumors accounted for 9.1% of all brain and 
CNS tumors, occurring at an incidence rate of 8 per 100,000 person-years [78].  
 
In a cohort of 1010 women and 1269 men with pituitary adenomas, in Swedish Cancer 
Registry between 1958 and 1991, observed significant increase in the age-standardized 
incidence of pituitary adenomas from approximately 6 cases/million inhabitants in 1958 
to 11cases/million inhabitants in 1991, which suggest a doubling in the annual incidence 
of pituitary adenoma [79]. Existing epidemiological data suggest that the incidence of 
pituitary tumor is rising but no conclusion can be derived from the current literature and 
the true incidence of pituitary tumor is difficult to establish with certainty. 
 
 
2.2.4 Etiology of brain tumors 
 
Just as in the case of many other cancers, the etiology of all subtypes of brain tumor 
remains largely unknown and research into it is ongoing but studies do suggest that 
many different factors may be associated with them. 
 
The well-established etiological factors for all types of brain neoplasm are high-dose 
ionizing radiation with most of the evidence coming from the survivors of the atomic 
bomb explosion in Japan [80] and a report from childhood cancer survivor study who 
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received cranial radiotherapy [81]. Survivors of the atomic bomb in Hiroshima and 
Nagasaki have been studied for different cancer types following exposure from blasts. A 
statistically significant dose response was observed for all nervous system tumors 
combined and a clear suggestion of a dose response for schwannoma was seen. About 4 
of the 34 pituitary tumors were estimated to be related to radiation exposure. [80] 
Moreover, the association between ionizing radiation exposure and the risk was found 
to be stronger for meningiomas than for gliomas [62]. The largest study of CNS tumors 
in survivors of childhood cancer also found that the risk of meningioma was strongly 
and linearly related to dose of radiation [81]. 
 
A small proportion of brain tumors are also related to rare hereditary conditions such as 
neurofibromatosis 1 and 2 (NF1 and NF2), tuberosis sclerosis, Cowden’s disease, von 
Hippel-Lindau disease and less frequently Li-Fraumeni syndrome, Turcot’s and 
Gorlin’s syndrome [82]. Certain inherited syndromes such as tuberous sclerosis, 
neurofibromatosis type 1 and 2, nevoid basal cell carcinoma syndrome, and syndromes 
involving adenomatous polyps, account for approximately 1–2% of all tumours [83]. 
However, the limited findings available so far have failed consistently to identify life 
time risk of brain tumors for carriers of these syndromes. A large pooled analysis found 
an increase in a twofold risk of glioma in first degree relatives of glioma patients [84]. 
 
No association between smoking or alcohol consumption and increased risk of 
intracranial tumors has been reported [83]. Maternal smoking during pregnancy does 
not appear to be strongly linked to brain tumours according to the meta-analysis of 6566 
subjects from 12 epidemiological studies [85] However, a later prospective study 
supported the role of maternal smoking during pregnancy in the etiology of childhood 
brain tumors [86].  
 
A meta-analysis on the association between excess body weight and the risk of 
meningioma has shown that meningioma risk is higher in obese (body mass index: BMI 
30+) females, compared with healthy weight (BMI 18.5-25) females but due to limited 
number of studies, the association remains unconfirmed [87]. 
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N-nitroso compounds formed by the reaction of amines and amides have been identified 
as potent nervous system carcinogens in animal models [62]. For humans, assessing N-
nitroso compound exposure is difficult because they are extremely common in 
endogenous and exogenous sources. Studies of diet and vitamin supplementation have 
provided mixed support for the hypothesis that dietary N-nitroso compounds might 
influence the risk of either childhood or adult brain tumors [62,83,88]. In some studies, 
a consistent inverse association was observed for a combined intake of coffee and tea 
and the risk of glioma but needs to be confirmed in detail [89,90]  
 
A large prospective study with over a million postmenopausal women to examine the 
relation between the use of hormone replacement therapy (HRT) and the incidence of 
central nervous system tumors (CNS) found that the incidence of CNS tumors was 
slightly (statistically significantly) increased in the current users of HRT particularly in 
the users of estrogen only therapy when compared to never users. In the analysis by 
tumor type, there was no significant difference between tumors specified as glioma, 
meningioma and acoustic neuroma [91]. 
 
In experimental animal models, brain tumours can be induced by a number of different 
viruses such as retroviruses and adenoviruses but there is little evidence for this 
occurring in humans. In utero infections with influenza and chicken pox have been cited 
as a risk factor but the association is not so strong [92]. 
 
Serious head trauma has long been suspected to be related to some type of brain tumors. 
Some studies have shown an apparently increased risk during the first year of serious 
head injury which might be due to increased early detection but does not show any 
association in subsequent years [93].  
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2.3 Electromagnetic radiation 
 
2.3.1 Nature and sources of electromagnetic radiation 
 
Electromagnetic radiation is ubiquitous in modern society. There are many natural and 
man-made sources of electromagnetic radiation. Natural sources include earth’s magnet-
ic field and man-made sources encompass radio stations, mobile phone base stations, 
TV antennas, microwaves, radars and other electrical appliances [94]. Radiofrequency 
(RF) radiation is a form of electromagnetic radiation. Within the electromagnetic spec-
trum, there is some variation in the classification of frequency bands but typically ra-
diofrequency electromagnetic fields (RF-EMF) cover the frequency range from 100 
KHz to 300GHz [95].  
 
 
Exposure to ionizing radiation such as x-rays and gamma rays is known to cause DNA 
damage by breaking chemical bonds in molecules [96]. However, no consistent evi-
dence has been demonstrated that non-ionizing radiation increases the risk for any of the 
brain or other head tumors [97]. The International Commission on Non-Ionizing Radia-
tion Protection (ICNIRP) formulated guidelines in limiting exposure to protect people 
from the suspected harmful effects of RF radiation that covered the frequency range up 
to 300 GHz [98].The guidelines published in 1998 were revised and in 2010, they is-
sued new guidelines for the frequency range 1Hz to 100 kHz which replaces the low-
frequency part of the 1998 guidelines [99]. The ICNIRP guidelines are based on an 
analysis of all relevant scientific literature, including both thermal and non-thermal 
studies. The harmful effects are due to the temperature rise in tissue after the absorption 
of RF radiation. The guidelines include a substantial safety margin for limiting public 
exposure as the public exposure limit with regard to RF caused temperature rise has 
been set at one tenth or below of the value where harmful effects can occur. [98] 
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2.3.2 Mobile phone as a source of electromagnetic radiation 
 
Currently, mobile phones are one of the most important sources of radiofrequency ra-
diation besides broadcasting radio and television signals, microwaves and other electri-
cal appliances. Mobile phones emit RF-EMF during transmission phase (i.e. when 
speaking during a phone call), which are non-ionizing and cannot cause damage to 
DNA (mutations). However, they have some thermal effects in contacts with the human 
body, raising the temperature in the tissues. This is the only established mechanism for 
biological effect of radiofrequency radiation. If there is an effect of mobile phone use at 
all, then it would be based on tumor promotion or progression rather than initiation 
[100]. 
 
 
Specific absorption rate (SAR), measures the level of exposure to mobile phone radia-
tion and it is expressed as W/kg (power per unit mass of body tissue). The SAR distri-
bution appears to decrease very rapidly with increasing depth, on average to a tenth with 
in the 5cm distance of brain tissue [101]. ICNIRP has given recommendations for SAR 
value limits to such a level that the excess temperature rise remains below 1degree Cel-
sius. The SAR level has been set to 0.08 W/kg for whole body exposure for the general 
public, 2W/kg for local exposure to the head and torso, and 4W/kg for local exposure to 
the limbs. A maximum SAR of 2 W/kg has been set as the highest value for localized 
exposure from mobile phone [98]. However, the SAR from a mobile phone varies with 
a range from about 0.0001 to 2W/kg. This variation appears due to the several determi-
nants of SAR value such as the output power of the phone, phone model, positioning of 
the phone, distance between the phone and the exposed tissues and network characteris-
tics [102]. 
 
 
In Europe, two principal mobile phone network types have been used: analogue (Nordic 
Mobile Telephone, NMT) which operates on 450/900 MHz frequencies and digital 
(Global System for Mobile Communications, GSM) operating at 900/1800 MHz. In 
addition to NMT and GSM telephones, third and fourth generation mobile phones have 
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been introduced; however, only exposure to NMT or GSM mobile phones are addressed 
in this thesis. 
 
The NMT and GSM systems operate in different power level as NMT phones emit 
radiation at a constant level (1W), whereas GSM use pulsed signals. The maximum 
transmission power of GSM phones is 0.25 W at 900 MHz frequency and 0.125W at 
1800 MHz frequency. The GSM system uses adaptive power control (APC) to reduce 
output power. A recent study has shown power reduction to around 50% (ranging from 
35 to 70%, depending on the country) of the maximum power levels in both 900 and 
1800MHz frequency bands. [103] 
 
Some expert groups have mentioned that the use of hands-free devices minimizes expo-
sure by limiting the number and duration of phone calls [87]. In addition, there will be 
lower exposure to radiofrequency fields than someone holding the handsets against their 
head. The use of hands-free device considerably reduces the SAR in the head by a factor 
of 20–100 [102].  
 
 
 
2.4 Mobile phones and brain tumors 
 
There have been numerous studies to examine the association between mobile phone 
use and the risk of brain tumours [3-14, 18-22,35,46-50,54-62,64-67,69,95,97,100-103]. 
Most studies are based on case-control design [6-13, 18-22, 35] and only few are cohort 
studies [105, 106]. Most of the studies rely on participants’ self-report for exposure 
assessment, with few exceptions using telephone company records [7,105,107]. 
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The largest case-control study of mobile phone use and brain tumor, the INTERPHONE 
study, reported a reduced odds ratio for glioma [OR 0.81; 95% CI: 0.70–0.94], 
meningioma (OR 0.79; 95% CI: 0.68–0.91) and acoustic neuroma 0.85 (95% CI: 0.69‐
1.04) between ever having been a regular mobile phone user and a never regular user. 
Although, the risk was not elevated for longer duration of use (>10 years), there were 
some indications of an increased risk of glioma in the temporal lobe than any other 
lobes of the brain at the highest exposure levels but biases such as recall bias and error 
prevented causal interpretation [108].  
 
A large nationwide cohort study to investigate cancer risk among Danish mobile phone 
users linked billing information for more than 358,000 cell phone subscribers between 
1982-1995. After following for up to 21 years, no association was found between 
mobile phone use and the incidence of glioma, meningioma or acoustic neuroma among 
either short-term or long-term users. [105,106] 
 
A large prospective study of middle-aged UK women, the Million Women Study, found 
that mobile phone use was not associated with an increased risk of glioma and 
meningioma. However, an increased risk (RR 1.88, 95% CI: 1.14–3.11) was found for 
acoustic neuroma in those who had used a mobile phone for more than 5 years. This 
significantly increased risk among long-term users remained unconfirmed, as the risk 
for acoustic neuroma was not significantly increased when the results were combined 
with previous Danish prospective study. [22] 
 
Gliomas, meningiomas and acoustic neuromas are among the most commonly 
investigated brain tumors in relation to mobile phone use. Pituitary tumours have not 
been paid as much attention as gliomas and meningiomas. A previous analysis of 
Japanese Interphone study reported no association between mobile phone and pituitary 
tumors [20]. Another study, based on 291 pituitary tumor cases and 630 controls from 
Southeast England also found no association with any aspect of mobile phone use [21]. 
A recent study, with a large UK cohort of middle aged women found increased relative 
risk for pituitary tumors among short-term users (duration less than 5 years) (RR 
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2.31,95% CI:1.31-4.06), but there was no evidence of increasing trend in risk with 
increasing duration of use [22]. 
 
The Surveillance, Epidemiology and End Results (SEER) program of the National 
Cancer Institute, which tracks cancer incidence in the United States, shows that despite 
the sharp increase in mobile phone use in the U.S between 1987 and 2008, the overall 
age-adjusted incidence of brain cancer did not increase [109]. Similar results have been 
reported from the Nordic countries [12, 66] and the UK [35]. 
 
It can be concluded from all the literature that there is a lack of evidence of an increased 
risk of any types of brain tumor associated with mobile phone use. However, for slow-
growing tumors, the latency period is still too short to draw valid conclusions. A large 
prospective cohort study of mobile telephone users (COSMOS) was launched in 2010 in 
five European countries to monitor possible health risks related to long-term mobile 
phone use among a large group of mobile phone users. It will take some time to obtain 
results from this study as the mobile phone users will be followed for 20 
+ 
years [110]. 
 
 
2.5 Mobile phone use and other cancers 
 
Apart from glioma, meningioma, acoustic neuroma and pituitary adenoma, some 
epidemiological studies have also focused on salivary gland tumors, leukemia or 
lymphoma, testicular cancer and intra-temporal facial nerve tumors. 
 
Two population-based case control studies in Denmark and Sweden concluded that 
mobile phone use is not related to an increased risk of parotid gland tumors [111]. 
Similarly, one study with 69 cases and 262 randomly recruited controls found no 
association (OR 0.8, 95% CI, 0.4-1.5) between mobile phone use and parotid gland 
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tumor for light to moderate users, but provided little information on long-term users 
[112].However in contrast, Israeli INTERPHONE study with 402 benign and 58 
malignant incident cases and 1,266 controls in 2001-2003 suggested a positive 
association between cellular phone use and parotid gland tumors [16].  
 
Regarding lymphoma, no consistent pattern of an increased risk was found [15,113]. 
There have been only a few studies for leukemia. A case-control study in South East 
England found no association between mobile phone use and leukemia. A non-
significantly raised risk (OR 1.87, 95% CI, 0.96-3.63) was found in heavy users [17]. 
Regular cellular phone use does not appear to be associated with intra-temporal facial 
nerve tumor [114] or testicular cancer [115]. 
 
 
2.6 Results of the meta-analysis from previous studies 
Author has noted some reports of the published meta-analysis regarding the effect of the 
mobile phone use on brain tumor risk and is presented below: 
First 
Author 
(last 
name, 
year) 
No of 
studies 
OR, 
glioma 
(95 % 
CI) 
OR, 
meningioma 
(95% CI) 
OR, 
acoustic 
neuroma 
(95% CI) 
OR >10 yrs of 
use 
(95% CI) 
Comments 
Lahkola 
2006 
[116] 
12 0.96 
(0.78-
1.18) 
0.87(0.72-
1.05) 
1.07(0.89-
1.30) 
- No indication 
of substantially 
increased risk 
of intracranial 
tumors from 
mobile phone 
use for a 
period of at 
least 5 years. 
Hardell, 
2008 
[117] 
10-
glioma 
7-
meningio
ma 
0.9(0.8-
1.1) 
0.8 
(0.7-0.99) 
0.9(0.7-
1.1) 
1.2(0.8-1.9) for 
glioma 
1.3(0.9-1.8) for 
meningioma 
and 
Provided a 
consistent 
pattern of 
association 
between 
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9-
acoustic 
neuroma 
1.3(0.6-2.8) for 
acoustic 
neuroma 
mobile phone 
use and 
ipsilateral 
glioma and 
acoustic  
neuroma using 
≥10 years 
latency period 
Kan, 
2008 
[118] 
9 low 
grade 
glioma 
1.14 
(0.91-
1.43) 
high 
grade 
glioma 
0.86 
(0.70-
1.05) 
0.64 
(0.56-0.74) 
0.96(0.83-
1.10) 
From 5 
studies-
1.25(1.01-
1.54) 
No overall 
increased risk 
of brain tumors 
among mobile 
phone users. 
Elevated risk 
after long term 
exposure 
awaits 
confirmation 
by future 
studies 
Ahlbom, 
2009 
[97] 
14-
Glioma 
14- 
meningio
ma 
13-
Acoustic 
neuroma 
Short 
term use:  
1.0 
 (0.9–1.1 
 
Short term 
use: 
0.8(0.7–0.9) 
Short term 
use 1.0 
(0.7-1.4) 
 
For glioma:  
1.1 (0.8–1.4) 
For 
meningioma: 
1.2 (0.7–2.2). 
For 
Acoustic 
neuroma: 
1.4(0.7-
2.5) 
 
laterality 
analyses were 
also covered 
but these were 
difficult to 
interpret due to 
methodologica
l problems 
such as recall 
bias 
Repacholi 
2012 
[119] 
8 studies 
for 
glioma 
4-
meningio
ma 
8 for 
acoustic 
Short 
term use 
(1–6 
years) 
 
1.03 
(0.86–
1.24)  
 
 
 
0.82 (0.72–
0.94)  
  
 
 
0.99 (0.70-
1.41) 
For glioma 
1.40(0.84-2.31)  
For 
meningioma 
1.25, 
(0.51–3.10)  
For acoustic 
There is very 
limited data 
available for 
long-term use 
of mobile 
phone. 
 
All results are 
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neuroma neuroma 
 1.37( 0.74–
2.52)  
obtained after 
combining 
Hardell et al. 
studies and 
Interphone 
studies 
Lagorio, 
2014 
[120] 
47 
studies 
(17 on 
glioma, 
15 on 
meningio
ma, 15 
on 
acoustic 
neuroma 
No 
increased 
risk was 
observed 
among 
short 
term and 
medium 
term 
users in 
any 
meta-
analysis 
Decreased 
risk was 
observed in 
almost all 
meta-
analysis 
Moderate 
to high 
degree of 
heterogene
ity across 
studies 
detected. 
The 
combined 
relative 
risks tend 
to increase 
with 
increasing 
time since 
start of use 
The combined 
relative risks 
ranged 
between 0.98 
(0.75–1.28) 
and 1.11 
(0.86–1.44) for 
meningioma 
 For glioma: 
1.19 (95% CI 
0.86–1.64) and 
1.40 
(0.96–2.04) 
For Acoustic 
Neuroma: 1.14 
(0.65–1.99) to 
1.33 (0.65–
2.73) 
47 studies 
were classified 
in to 5 groups 
(i.e US studies, 
Finnish  
studies, Örebro 
series,Interpho
ne study and 
Danish cohort 
study) 
  
Detected a 
moderate to 
high degree of 
heterogeneity 
across studies 
of glioma and 
acoustic 
neuroma and 
no or low 
heterogeneity 
across studies 
of meningioma  
 
 
A meta-analysis of 11 long-term epidemiological studies examining long-term cell 
phone use (≥10 years) and the risk of developing brain tumor including ‘Hardell group 
studies’ and ‘Interphone group studies’  gave an overall ORs (95% CI)  for glioma (OR, 
1.3; CI, 1.1-1.6), meningioma(OR, 1.1; CI, 0.8-1.4), acoustic neuroma (OR, 1.3; CI, 
0.97-1.9) [121]. 
 
Another meta-analysis to evaluate the brain tumor risk among long-term users of 
cellular telephones with 2 cohort studies and 16 case control studies found increased 
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odd ratio especially for ipsilateral exposure, acoustic neuroma (ORs 2.4;95% CI 1.1-
5.3) and for glioma(ORs 2;95% CI 1.2-3.4) [122]. 
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3. WORK DESCRIPTION 
 
My interest in cancer research began when I was doing my undergraduate degree. 
Several years later, I got chance to fulfill this desire, and currently I am pursuing this 
interest as a degree student under the supervision of Prof. Anssi Auvinen. My first true 
research experience began as a summer apprentice during June, July and August 2014. I 
feel really lucky, proud, privileged and honored to be offered work placement for three 
months on University premises and stretch myself personally and professionally. 
Basically, I was working in Interphone project which is the largest case-control study on 
the topic, aiming to investigate whether the mobile phone use increases the risk of 
intracranial tumors. It has cemented my interest and I chose to write my thesis on the 
same project focusing on pituitary tumor risk. 
 
I was provided with pituitary tumor case list and the list of controls. At first my task 
was to select suitable cases that meet our study pre-requisites. Out of the 85 interviewed 
cases, I excluded 5 cases because they did not meet the inclusion criteria. We had 1232 
controls, out of which we selected 240 controls matched to cases by age, sex, region of 
residence and date of interview. The total number of study subjects included in the 
analysis was 320. Our biostatistician Jani Raitanen helped me throughout the process, 
then data sets were ready for analysis. Analyses were almost completed within 2 
months, however a few were added later on as per suggestions from co-authors. The 
software, Stata that I used was totally new for me; I was familiar with SPSS only. At the 
beginning I was afraid of using new software but Jani kept it as simple as possible. It 
was such a great opportunity to learn basic analysis in Stata. Now, I have developed 
confidence to work on this software. 
 
Then I started writing report and preparing manuscript for journal article. I went through 
lots of previous related articles and gain some ideas about those studies and my 
supervisor was available all the time to guide, encourage and motivate me during data 
analysis, interpretation and writing paper. He arranged all the specific tools for me and 
kept me in track for the whole period.  
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Being a presenting author, I had huge responsibilities to come up with the well-polished 
manuscript. Never having been exposed with such domain, I was challenged but equally 
excited to work with expert co-authors. Tiina Salminen and Anna Lahkola have 
provided intellectual input for manuscript correction. The comments and feedbacks 
were really very important and useful for me. It was the collective continuous effort of 
the author and co-authors to complete this manuscript successfully. Now, we have 
submitted manuscript for Acta Oncologica, and we are looking forward for receiving 
reviewer comments and eventually its publication. 
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